Logo

Latest Press Releases

March 8, 2023
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference

February 14, 2023
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy 

December 5, 2022
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting

More Press Releases

photo of neuron

In the news

February 17, 2023
The New Era of Life Sciences 2023

January 19, 2023
The News That Mattered in 2022: Neurology Today Editorial Board Top Picks

December 22, 2022
Cell Therapy NRTX-1001 Shows Significant Effect on Drug-Resistant Epilepsy in Early Data

More News Articles

Events

March 15, 2023 at 2:00 PM ET
Oppenheimer 33rd Annual Healthcare Conference

More Events

  • About
    • Mission / Vision
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Investors
  • Technology
    • Approach
    • Manufacturing
    • Publications
  • Pipeline
    • Programs
  • Clinical Trials
    • Phase I/II NRTX-1001 for epilepsy
    • Phase I/II NRTX-1001 for epilepsy on clinicaltrials.gov
  • News
    • Press Releases
      • 030823
      • 021423
      • 120522
      • 112122
      • 092122
      • 062922
      • 061722
      • 052622
      • 040422
      • 040122
      • 010522
      • 121321
      • 120321
      • 111821
      • 110821
      • 110421
      • 102022
      • 062221
      • 061621
      • 041921
      • 103119
      • 121417
      • 120117
    • In the News
    • Events
  • Careers
    • Culture
    • Values
    • Benefits
    • Visiting Scientists & Internship programs
    • Job Opportunities
  • Contact
  • Home
  • About
    • Mission / Vision
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Investors
  • Technology
    • Approach
    • Manufacturing
    • Publications
  • Pipeline
    • Programs
  • Clinical Trials
    • Phase I/II NRTX-1001 for epilepsy
    • Phase I/II NRTX-1001 for epilepsy on clinicaltrials.gov
  • News
    • Press Releases
      • 030823
      • 021423
      • 120522
      • 112122
      • 092122
      • 062922
      • 061722
      • 052622
      • 040422
      • 040122
      • 010522
      • 121321
      • 120321
      • 111821
      • 110821
      • 110421
      • 102022
      • 062221
      • 061621
      • 041921
      • 103119
      • 121417
      • 120117
    • In the News
    • Events
  • Careers
    • Culture
    • Values
    • Benefits
    • Visiting Scientists & Internship programs
    • Job Opportunities
  • Contact
Logo
Neurona Therapeutics
170 Harbor Way
South San Francisco, CA 94080
info@neuronatx.com
LinkedIn
© 2023 Neurona Therapeutics All rights reserved.
  • Terms of Use
  • Privacy Policy
Website Design: Hane Chow, Inc.